NCT02514174 - Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 18, 2015

Primary Completion Date

March 28, 2019

Study Completion Date

April 25, 2019

Conditions

Carcinoma, Non-Small-Cell LungErbB Receptors

Interventions

DRUG

Afatinib

afatinib starting at 30 mg daily dose

Trial Locations (10)

Montefiore Medical Center, The Bronx

Lankenau Medical Center, Wynnewood

University of Miami, Miami

Ingalls Memorial Hospital, Harvey

Mayo Clinic-Arizona, Scottsdale

Los Angeles Hematology Oncology Medical Group, Los Angeles

City of Hope, Duarte

Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc., Fountain Valley

Pacific Cancer Medical Center, Inc., Anaheim

Baystate Health D'Amour Center for Cancer Care, Springfield